ArticleTherapeutic advances in gastroenterology2019

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.

Joao Goncalves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.